<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03790111</url>
  </required_header>
  <id_info>
    <org_study_id>LX1606.1-207-BTC</org_study_id>
    <secondary_id>LX1606.207</secondary_id>
    <secondary_id>LX1606.207</secondary_id>
    <nct_id>NCT03790111</nct_id>
  </id_info>
  <brief_title>A Safety and Efficacy Study of XERMELO® + First-line Chemotherapy in Patients With Advanced Biliary Tract Cancer</brief_title>
  <acronym>TELE-ABC</acronym>
  <official_title>A Phase 2, Multicenter, Open-label, Safety and Efficacy Study of XERMELO® (Telotristat Ethyl) Plus First-line Chemotherapy in Patients With Locally Advanced, Unresectable, Recurrent or Metastatic Biliary Tract Cancer (BTC)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>TerSera Therapeutics LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>TerSera Therapeutics LLC</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Phase 2, multicenter, open-label, 2-stage study to assess the safety, tolerability, and&#xD;
      efficacy of XERMELO in combination with first-line (1L) therapy (cisplatin [cis] plus&#xD;
      gemcitabine [gem])&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A Phase 2, multicenter, open-label, 2-stage study to assess the safety, tolerability, and&#xD;
      efficacy of XERMELO in combination with first-line (1L) therapy (cisplatin [cis] plus&#xD;
      gemcitabine [gem]) in patients with unresectable, locally advanced, recurrent or metastatic&#xD;
      biliary tract cancer (intrahepatic or extrahepatic cholangiocarcinoma, gallbladder cancer),&#xD;
      who are naïve to tumor-directed therapy in the locally advanced or metastatic setting, and&#xD;
      for which treatment with 1L therapy (defined as a combination of cis/gem) is planned.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">March 13, 2019</start_date>
  <completion_date type="Anticipated">February 2024</completion_date>
  <primary_completion_date type="Anticipated">December 30, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free survival (PFS) rate</measure>
    <time_frame>Month 6</time_frame>
    <description>Patient progression is defined as the time from Baseline until the first determination of PD by central radiologic at 6 months reading using RECIST v1.1 or death from any cause</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of treatment emergent adverse events</measure>
    <time_frame>Through study completion, approximately 2 years</time_frame>
    <description>All Treatment Adverse Events at 2 years</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>Month 6</time_frame>
    <description>Survival at 6 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>Month 12</time_frame>
    <description>Survival at 12 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival (PFS) rate</measure>
    <time_frame>Month 12</time_frame>
    <description>Patient progression is defined as the time from Baseline until the first determination of PD by central radiologic reading using RECIST v1.1 or death from any cause at 12 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease control rate (DCR)</measure>
    <time_frame>Month 6</time_frame>
    <description>Defined as complete response (CR) + partial response (PR) + stable disease (SD) at month 6</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease control rate (DCR)</measure>
    <time_frame>Month 12</time_frame>
    <description>Defined as complete response (CR) + partial response (PR) + stable disease (SD) at month 12</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease control rate (DCR)</measure>
    <time_frame>Throug at year 2h study completion, approximately 2 years</time_frame>
    <description>Defined as complete response (CR) + partial response (PR) + stable disease (SD) at 2 years</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective response rate (ORR)</measure>
    <time_frame>Month 6</time_frame>
    <description>(CR) + partial response (PR) at Months 6</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective response rate (ORR)</measure>
    <time_frame>Month 12</time_frame>
    <description>(CR) + partial response (PR) at Month 12</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective response rate (ORR)</measure>
    <time_frame>Through study completion, approximately 2 years</time_frame>
    <description>(CR) + partial response (PR) at 2 years</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in plasma 5-hydroxyindoleacetic acid (5-HIAA)</measure>
    <time_frame>Month 6</time_frame>
    <description>Baseline to month 6 plasma level 5-hydroxyindoleacetic acid (5-HIAA)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in plasma 5-hydroxyindoleacetic acid (5-HIAA)</measure>
    <time_frame>Month 12</time_frame>
    <description>Baseline to month 12 plasma level 5-hydroxyindoleacetic acid (5-HIAA)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in plasma 5-hydroxyindoleacetic acid (5-HIAA)</measure>
    <time_frame>Through study completion, approximately 2 years</time_frame>
    <description>Baseline to month 12 plasma level 5-hydroxyindoleacetic acid (5-HIAA)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in carbohydrate antigen 19-9 (CA 19-9)</measure>
    <time_frame>Month 6</time_frame>
    <description>Change from Baseline to month 6 in plasma carbohydrate antigen 19-9 (CA 19-9)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in carbohydrate antigen 19-9 (CA 19-9)</measure>
    <time_frame>Month 12</time_frame>
    <description>Change from Baseline to month 12 in plasma carbohydrate antigen 19-9 (CA 19-9)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in carbohydrate antigen 19-9 (CA 19-9)</measure>
    <time_frame>Through study completion, approximately 2 years</time_frame>
    <description>Change from Baseline to 2 years in plasma carbohydrate antigen 19-9 (CA 19-9)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Weight change from Baseline</measure>
    <time_frame>Month 6</time_frame>
    <description>Weight measurement</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Weight change from Baseline</measure>
    <time_frame>Month 12</time_frame>
    <description>Weight measurement</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Weight change from Baseline</measure>
    <time_frame>Through study completion, approximately 2 years</time_frame>
    <description>Weight measurement</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in plasma albumin</measure>
    <time_frame>Month 6</time_frame>
    <description>Baseline to month 6 plasma albumin levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in plasma albumin</measure>
    <time_frame>Month 12</time_frame>
    <description>Baseline to month 12 plasma albumin levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in plasma albumin</measure>
    <time_frame>Through study completion, approximately 2 years</time_frame>
    <description>Baseline to 2 years plasma albumin levels</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">53</enrollment>
  <condition>Biliary Tract Cancer</condition>
  <arm_group>
    <arm_group_label>Xermelo 250mg plus 1L therapy for a week, then Xermelo 500mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Xermelo 250mg plus 1L therapy for a week, then Xermelo 500mg plus 1L therapy for the duration of the study</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>telotristat ethyl</intervention_name>
    <description>XERMELO (telotristat ethyl) tablets administered as 250 mg (1 x 250-mg tablet) tid plus 1L therapy for 7 days, then XERMELO (telotristat ethyl) tablets administered as 500 mg (2 x 250-mg tablets) tid plus 1L therapy for the duration of the study</description>
    <arm_group_label>Xermelo 250mg plus 1L therapy for a week, then Xermelo 500mg</arm_group_label>
    <other_name>telotristat ethyl + (cisplatin [cis] plus gemcitabine [gem])</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female adults, ≥18 years of age. Patients of childbearing potential must agree&#xD;
             to use an adequate method of contraception during the study and for 30 days after the&#xD;
             last dose of XERMELO&#xD;
&#xD;
          -  Histopathologically or cytologically-confirmed, unresectable, locally advanced,&#xD;
             recurrent, or metastatic biliary tract cancer (BTC)&#xD;
&#xD;
          -  Naïve to tumor-directed therapy in locally advanced, unresectable, or metastatic&#xD;
             setting&#xD;
&#xD;
          -  Measurable disease&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status 0-1&#xD;
&#xD;
          -  Plans to initiate treatment with 1L therapy (cisplatin plus gemcitabine)&#xD;
&#xD;
          -  Ability to provide written informed consent prior to participation in any&#xD;
             study-related procedure&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior exposure to XERMELO, telotristat ethyl, telotristat etiprate, LX1032, or LX1606&#xD;
&#xD;
          -  Primary tumor site in the ampulla of Vater&#xD;
&#xD;
          -  Treatment with photodynamic therapy for localized disease or to relieve biliary&#xD;
             obstruction in the presence of metastatic disease within the past 30 days&#xD;
&#xD;
          -  Hematology laboratory values of: a. Absolute neutrophil count (ANC) ≤1,500 cells/mm^3;&#xD;
             or b. Platelets ≤100,000 cells/mm^3; or c. Hemoglobin (Hgb) ≤9 g/dL; or d. White blood&#xD;
             count (WBC) ≤3,000 cells/mm^3&#xD;
&#xD;
          -  Hepatic laboratory values of aspartate aminotransferase (AST) or alanine&#xD;
             aminotransferase (ALT): a. &gt;5 x upper limit of normal (ULN) if patient has documented&#xD;
             history of hepatic metastases; or b. &gt;2.5 x ULN if no liver metastases are present&#xD;
&#xD;
          -  Serum albumin &lt;2.8 g/dL&#xD;
&#xD;
          -  Total bilirubin &gt;1.5 x ULN or &gt;1.5 mg/dL&#xD;
&#xD;
          -  Prothrombin time (PT) or international normalized ratio (INR) &gt;1.5 x ULN&#xD;
&#xD;
          -  Serum creatinine or serum urea &gt;1.5 x ULN&#xD;
&#xD;
          -  Estimated glomerular filtration rate (eGFR) &lt;50 mL/min&#xD;
&#xD;
          -  Positive pregnancy test, pregnant, or breastfeeding&#xD;
&#xD;
          -  Any other clinically significant laboratory abnormality that would compromise patient&#xD;
             safety or the outcome of the study&#xD;
&#xD;
          -  Any clinically significant and/or uncontrolled cardiac-related abnormality that would&#xD;
             compromise patient safety or the outcome of the study&#xD;
&#xD;
          -  Myocardial infarction within the past 6 months&#xD;
&#xD;
          -  Active bleeding diathesis&#xD;
&#xD;
          -  Life expectancy ≤3 months&#xD;
&#xD;
          -  Current complaints of persistent constipation or history of chronic constipation,&#xD;
             bowel obstruction or fecaloma within the past 6 months&#xD;
&#xD;
          -  Receiving chronic treatment with corticosteroids ≥5 mg of prednisone per day (or&#xD;
             equivalent) or other immunosuppressive agent(s)&#xD;
&#xD;
          -  History and/or uncontrolled hepatitis B surface antigen (HBsAg), hepatitis C antibody&#xD;
             (HCV Ab), or human immunodeficiency virus (HIV)-1 or HIV-2&#xD;
&#xD;
          -  History of substance or alcohol abuse within the past 2 years&#xD;
&#xD;
          -  History of galactose intolerance, deficiency of Lapp lactase, or glucose-galactose&#xD;
             malabsorption&#xD;
&#xD;
          -  History of malignancy or active treatment for malignancy within 5 years&#xD;
&#xD;
          -  Receipt of live, attenuated vaccine or close contact with someone who has received a&#xD;
             live, attenuated vaccine within the past 1 month&#xD;
&#xD;
          -  Receipt of any investigational agent or study treatment (ie, any treatment or therapy&#xD;
             not approved by the FDA for the treatment of BTC) within the past 30 days&#xD;
&#xD;
          -  Receipt of any protein or antibody-based therapeutic agents within the past 3 months&#xD;
&#xD;
          -  Treatment with any tumor-directed therapy within the past 6 months with curative&#xD;
             intent&#xD;
&#xD;
          -  Existence of any surgical or medical condition that, in the judgment of the&#xD;
             Investigator, might compromise patient safety or the outcome of the study&#xD;
&#xD;
          -  Presence of any clinically significant findings (relative to the patient population)&#xD;
             during review of medical history or upon physical exam that, in the Investigator's or&#xD;
             Medical Monitor's opinion, would compromise patient safety or the outcome of the study&#xD;
&#xD;
          -  Evidence of brain metastases&#xD;
&#xD;
          -  Unable or unwilling to communicate or cooperate with the Investigator for any reason&#xD;
&#xD;
          -  Employee of Sponsor or clinical site, or relative of any member of a clinical site's&#xD;
             staff&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Renuka Iyer, M.D.</last_name>
    <role>Study Chair</role>
    <affiliation>Roswell Park Cancer Institute</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Richard Kim, M.D.</last_name>
    <role>Study Chair</role>
    <affiliation>H. Lee Moffitt Cancer Center and Research Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>TerSera Investigational Site</name>
      <address>
        <city>Gilbert</city>
        <state>Arizona</state>
        <zip>85234</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>TerSera Investigational Site</name>
      <address>
        <city>Fullerton</city>
        <state>California</state>
        <zip>92835</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>TerSera Investigational Site</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32610</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>TerSera Investigational Site</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>TerSera Investigational Site</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>TerSera Investigational Site</name>
      <address>
        <city>Westwood</city>
        <state>Kansas</state>
        <zip>66205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>TerSera Investigational Site</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40536</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>TerSera Investigational Site</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02118</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>TerSera Investigational Site</name>
      <address>
        <city>Grand Rapids</city>
        <state>Michigan</state>
        <zip>49503</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>TerSera Investigational Site</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14263</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>TerSera Investigational Site</name>
      <address>
        <city>Lake Success</city>
        <state>New York</state>
        <zip>11042</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>TerSera Investigational Site</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>TerSera Investigational Site</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>TerSera Investigational Site</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>December 25, 2018</study_first_submitted>
  <study_first_submitted_qc>December 27, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">December 31, 2018</study_first_posted>
  <last_update_submitted>February 22, 2021</last_update_submitted>
  <last_update_submitted_qc>February 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Biliary Tract Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

